Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Metastatic Castration-Resistant Prostate Cancer × relugolix × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3 Pathologic Complete Response 1 Neoplasm, Residual 1 Metastatic Castration-Resistant Prostate Cancer 1 Endometriosis 1 Adenocarcinoma 1

Interventions

relugolix 1 apalutamide 1 abiraterone 1 Prednisone 1 Methylprednisolone 1 Lutetium-177 1 Lutetium 1 Gonadotropin-Releasing Hormone 1 Docetaxel 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡